Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4490032 | 1.00 | CXCR4 (0.47) | CXCR4NPSR1KMT2AMEN1HTR2C | |
| SCHEMBL3013360 | 1.00 | CXCR4 (0.47) | CXCR4NPSR1KMT2AMEN1HTR2C | |
| SCHEMBL3013363 | 1.00 | CXCR4 (0.47) | CXCR4NPSR1KMT2AMEN1HTR2C | |
| SCHEMBL3280519 | 1.00 | CXCR4 (0.47) | CXCR4NPSR1KMT2AMEN1HTR2C | |
| SCHEMBL8298357 | 0.86 | CXCR4 (0.46) | CXCR4NPSR1KMT2AMEN1HTR2C | |
| SCHEMBL505521 | 0.85 | KDM4E (0.51) | — | |
| SCHEMBL856875 | 0.85 | KDM4E (0.51) | — | |
| SCHEMBL14721003 | 0.83 | CXCR4 (0.58) | CXCR4NPSR1KMT2AMEN1HDAC3 | |
| SCHEMBL8501612 | 0.80 | CXCR4 (0.66) | CXCR4NPSR1KMT2AMEN1HDAC3 | |
| SCHEMBL23522808 | 0.80 | SMN1; SMN2 (0.47) | KMT2AMEN1DPP4GRIN2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334304-B2 | Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-12-18 | — | — | US | disclosed |
| EP-1641782-B1 | HYDROXYCARBONYLPHENYL SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-03 | — | — | EP | disclosed |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-7732464-B2 | Heterocyclic substituted 4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-06-08 | — | — | US | disclosed |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | BOSMANS JEAN-PAUL RENE MARIE ANDRE | 2010-04-08 | — | — | US | disclosed |
| US-7652040-B2 | gastrointestinal disorders hypermotility, irritable bowel syndrome, constipation or diarrhea | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-26 | — | — | US | disclosed |
| US-7635706-B2 | 1-butyl-3-hydroxy4-piperidinyl)methyl 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylate and chemical intermediates; treating hypermotility, irritable bowel syndrome (IBS) constipation or diarrhea predominant IBS, pain and non-pain predominant IBS and bowel hypersensitivity | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-22 | — | — | US | disclosed |
| EP-1638961-B1 | HETEROCYCLIC SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE BENZAMIDES AS 5HT4-ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-18 | — | — | EP | disclosed |
| US-RE40793-E1 | Bicyclic benzamides of 3-or 4-substituted 4-(aminomethyl)-piperidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-7498347-B2 | Hydroxycarbonylphenyl substituted 4-(aminomethyl)-piperidine benzamides as 5HT4 antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| US-6750349-B2 | SUPERIOR GASTROKINETIC PROPERTIES | JANSSEN PHARMACEUTICS, N.V. (BE) | 2004-06-15 | — | — | US | disclosed |
| US-20040058958-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2004-03-25 | — | — | US | disclosed |
| EP-1000028-B1 | GASTROKINETIC MONOCYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2003-11-26 | — | — | EP | disclosed |
| US-6635643-B2 | For treating conditions which are related to impairment of gastric emptying | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-10-21 | — | — | US | disclosed |
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2003-04-24 | — | — | US | disclosed |
| US-6544997-B1 | E.g., hypermotility, irritable bowel syndrome, bowel hypersensitivity and the reduction of pain associated with gastrointestinal hypersensitivity and/or hyperactivity | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
| EP-0991410-B1 | GASTROKINETIC BICYCLIC BENZAMIDES OF 3- OR 4-SUBSTITUTED 4-(AMINOMETHYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-10-30 | — | — | EP | disclosed |
| US-6452013-B1 | FOR TREATING CONDITIONS WHICH ARE RELATED TO IMPAIRMENT OF GASTRIC EMPTYING | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-09-17 | — | — | US | disclosed |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | BOSMANS JEAN-PAUL RENE MARIE A (BE) | 2002-07-04 | — | — | US | disclosed |
| EP-1206938-A1 | Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)- piperdine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078427-A1 | Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | HRH2, ALK, CBR1 | CXCR4 2025/4885NPSR1 532/4885KMT2A 2566/4885 |
| US-20020086879-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | CBR1, ALK, CBR3 | CXCR4 1527/4885NPSR1 97/4885KMT2A 2330/4885 |
| US-20100087483-A1 | Aminosulfonyl Substituted 4-(Aminomethyl)-Piperidine Benzamides As 5HT 4-Antagonists | HTR4, HTR2B, HTR2C | CXCR4 1991/4885NPSR1 49/4885KMT2A 478/4885 |
| US-20100210657-A1 | Bicyclic Benzamides of 3-or 4-Substituted 4-(Aminomethyl)-Piperidine Derivatives | HRH2, HRH4, PGC | CXCR4 4685/4885NPSR1 656/4885KMT2A 1633/4885 |
| US-20040058958-A1 | Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives | ALK, HRH2, CBR1 | CXCR4 1978/4885NPSR1 337/4885KMT2A 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.